 Liver & Pancreas Tumor Center

Our team of specialty board-certified experts focuses exclusively on these rare and complex hepatopancreaticobiliary (HPB) cancers.

Designated by the National Pancreas Foundation, we are the region’s only NPF Center for Pancreatic Cancer.

What Sets Us Apart

- **Our experience** from the performance of high volumes of pancreas and liver resections
- **Quicker recovery** from minimally-invasive laparoscopic partial liver and pancreas resections
- **Optimal incorporation and sequencing** of state-of-the-art liver-directed therapies that improve survival and quality of life
- **Multidisciplinary care teams** employ neoadjuvant therapies to improve patient outcomes and make potentially curative surgery possible
- **Highly-skilled advanced endoscopists** that are fellowship trained and utilize endoscopic ultrasound for optimal staging and diagnosis
- **Latest diagnostic imaging** for early tumor detection
- **Clinical trials** that offer tomorrow’s promising treatments today
The Liver & Pancreas Tumor Center
Collective Expertise & Continued Collaboration
Within a Multidisciplinary Care Team

Co-Directors: Roderich Schwarz, MD, PhD and Renuka Iyer, MD

This center brings together a multidisciplinary team of specialists – surgical, medical and radiation oncologists among other specialists – who meet weekly to discuss and develop patient care strategies using evidence-based guidelines. A designated care coordinator and members of the supportive services care team including dietitians, social workers, palliative care and case managers, collectively create the full care plan for each individual patient to guide them on their cancer journey.

Our expert team uses the latest technologies and therapies to care for rare and complex hepatopancreatobiliary (HPB) conditions including:

- Primary liver cancer
- Pancreas cancer
- Bile duct and gallbladder cancer
- Ampullary and duodenal cancer
- Neuroendocrine tumors (carcinoid, islet)
- Metastatic tumors to the liver (colorectal, neuroendocrine and others)
- Cystic pancreatic and liver tumors
- Concerning strictures of pancreatic or bile ducts

Our 30-day mortality, length of hospital stay, and pneumonia rate after liver and pancreas surgery are among the best in the nation.

NOVEL CLINICAL RESEARCH STUDIES
We offer the latest therapies through clinical research studies.

For more information about current trials, call 716-845-RPMD (716-845-7763) or go to RoswellPark.org/clinical-trials/list.

Diagnostic and Interventional Services We Offer

Our range of diagnostic and therapeutic interventions is unmatched by any facility in Western New York and includes: liver-directed therapies, advanced biliary endoscopy, minimally invasive surgery and high-risk pancreatic screening with genetic counseling.

LIVER-DIRECTED THERAPIES
- Hepatectomy (minimally invasive and open)
- Bile duct resection and reconstruction
- NanoKnife Irreversible Electroporation (IRE)
- Microwave Ablation (MWA)
- Transarterial embolization with drug-eluting beads (DEB)
- Radioembolization (SIR-Spheres or Theraspheres )
- Precision-targeted radiation therapy

ADVANCED BILIARY ENDOSCOPY
- Endoscopic ultrasound and biopsy
- Therapeutic ERCP
- Biliary and enteric stents
- Endoscopic mucosal resection
- Internalization of external biliary stents
- Cholangioscopy

MINIMALLY INVASIVE SURGERY (laparoscopic and robot-assisted surgery)
- Liver and pancreas resections
- NanoKnife for pancreas and liver tumors
- Microwave ablation of liver tumors
- Intraoperative ultrasound
- Bowel resection
Expertise in Treating Neuroendocrine Tumors

Neuroendocrine tumors are more prevalent than pancreas and gastric cancers combined. Because of the few approved treatments and limited data for evidence-based medicine, these patients benefit from dedicated multidisciplinary care that includes therapeutic endoscopists, interventional radiologists, endocrinologists and surgical and medical oncologists who specialize in these unique tumors.

Studies have shown that outcomes are better when care is coordinated and optimally sequenced. Our approach includes:

- Surgical resection and/or ablative therapies
- Liver-directed therapies such as chemo- and radioembolization
- Novel imaging for neuroendocrine tumors using gallium-68 dotatate PET
- Medical treatments using sandostatin, lanreotide, targeted agents and temozolamide-based combinations
- Peptide receptor radionuclide therapy (PRRT)
- Clinical trials of novel drugs

Expertise in Treating Colorectal Cancer Liver Metastases

Multidisciplinary approaches at Roswell Park have expanded the proportion of patients eligible for surgical therapy from 10% reported in national databases to at least 30%. Our approach includes:

- Initial chemotherapy to shrink tumors and facilitate margin negative resection
- 2-stage liver resection for bilobar disease
- Portal vein embolization to allow more extensive liver surgery
- Transarterial radioembolization optimally sequenced with chemotherapy
- Ablative therapies such as microwave ablation or NanoKnife® Irreversible Electroporation (IRE)
- Clinical trials of novel chemotherapy, targeted and immunotherapy agents

Hepatocellular Cancer Treatments

- Surgical treatments. Compared to national averages, we operate on more high-risk patients with cirrhosis and HCC, with superior patient outcomes.
- Liver-directed therapies with microwave ablation, chemoembolization and/or radioembolization as both destination and “bridge to transplant” therapies.
- Novel trials incorporating immunotherapy into existing treatments, such as sorafenib with pembrolizumab for advanced HCC.

WHY ROSWELL PARK FOR RARE CANCERS?

We are the only comprehensive cancer center designated by the National Cancer Institute (NCI) outside of New York City.

A charter member of the National Comprehensive Cancer Network (NCCN). Our physicians sit on NCCN and Delphi Panels, and create the practice guidelines to treat liver, pancreas, bile duct and neuroendocrine tumors.

Designated by the National Pancreas Foundation as an NPF Center which recognizes Roswell Park as a premier facility for multidisciplinary treatment of pancreas cancer that treats the whole person, focusing on the best possible outcomes and improving quality of life.

Our physicians are endorsed for their expertise by leading organizations such as the Carcinoid Cancer Foundation, the Cholangiocarcinoma Foundation and the North American Neuroendocrine Tumor Society (NANETS).
Meet the Team

As a multidisciplinary comprehensive cancer center, we call upon highly skilled professionals from all areas of cancer care, dedicated to work collaboratively to treat the whole patient, not just the cancer.

ROS E WEL L P ARK C ARE N ET W ORK

NORTH TOWNS
Saif Soniwala, MD
Frederick Hong, MD
Adam Kotowski, MD
Michael Krabek, MD, PhD

SOUTH TOWNS
Mohamed El-Naghy, MD
Adam Kotowski, MD
Shashikant Lele, MD, FACOG
Mariola Poss, MD, FACS
Ilene Rothman, MD
Yasar Shad, MD, FACP

NIAGARA
Bhuvana Ramkumar, MD

JAMESTOWN
Peter Frederick, MD, FACOG
Jairus Ibabao, MD

UROLOGY
Prabhakara Somayaj, MD

BREAST SURGERY
Mariola Poss, MD, FACS

Surgical Oncology
1. Steven Hochwald, MD, MBA
2. Leonid Cherkassky, MD
3. Boris Kuveshinoft, MD, MBA
4. Moshim Kukar, MD
5. Roderich Schwarz, MD, PhD

Medical Oncology
1. Amy Early, MD, FACP
2. Christos Fountzilas, MD
3. Renuka Iyer, MD
4. Sarbjit Mukherjee, MD, MS

Radiation Oncology
1. David Mattson, MD

Gastroenterology
1. Andrew Bain, MD
2. Kevin Robillard, MD

Diagnostic & Interventional Radiology
1. Omar Hasan, MD
2. Michael Petroziello, MD
3. Charles Roche, MD
4. Garin Tomaszewski, MD

Nuclear Medicine
1. Dominick Lamonica, MD

Surgical Pathology
1. Charles LeVea, MD
2. Kazunori Kanefura, MD
3. Theresa Smith, DO

Endocrinology
1. Rajeev Sharma, MBBS, MD, FACE

Your patient may prefer to receive cancer care closer to home at one of Roswell Park’s Care Network practices. RoswellPark.org/CareNetwork

To speak with one of our HPB physicians, or to refer a patient, call the RPMD line at 716-845-RPMD (716-845-7763), Monday through Friday, 8 am-8 pm.